Literature DB >> 12238581

Comparison of procalcitonin with CRP and differential white blood cell count for diagnosis of culture-proven neonatal sepsis.

Janne Blommendahl1, Martti Janas, Seppo Laine, Ari Miettinen, Per Ashorn.   

Abstract

We analysed the utility of procalcitonin (PCT) assay, either alone or in combination with 2 simple blood assays, for the diagnosis of culture-proven neonatal septicaemia. Tests for serum PCT concentration, serum CRP concentration and blood immature to total neutrophil leucocyte ratio all had reasonable (58-77%) sensitivity, reasonable (62-84%) specificity, good (94-97%) negative predictive value and poor (16-24%) positive predictive value for the diagnosis of sepsis. Algorithms combining various tests produced slight improvements in sensitivity or specificity. Although the PCT test appeared to be useful for the diagnosis of neonatal sepsis in this small study, it did not offer any significant advantages over traditional tests for the diagnosis of infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12238581     DOI: 10.1080/00365540210147723

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  12 in total

1.  Use of the complete blood cell count in early-onset neonatal sepsis.

Authors:  Christoph P Hornik; Daniel K Benjamin; Kristian C Becker; Daniel K Benjamin; Jennifer Li; Reese H Clark; Michael Cohen-Wolkowiez; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

Review 2.  Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis.

Authors:  Evridiki K Vouloumanou; Eleni Plessa; Drosos E Karageorgopoulos; Elpis Mantadakis; Matthew E Falagas
Journal:  Intensive Care Med       Date:  2011-03-05       Impact factor: 17.440

Review 3.  Molecular assays for the diagnosis of sepsis in neonates.

Authors:  Mohan Pammi; Angela Flores; James Versalovic; Mariska Mg Leeflang
Journal:  Cochrane Database Syst Rev       Date:  2017-02-25

4.  Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children.

Authors:  Maja Pavcnik-Arnol; Sergej Hojker; Metka Derganc
Journal:  Intensive Care Med       Date:  2007-04-05       Impact factor: 17.440

5.  Evaluation of procalcitonin for diagnosis of neonatal sepsis of vertical transmission.

Authors:  José B López Sastre; David Pérez Solís; Vicente Roqués Serradilla; Belén Fernández Colomer; Gil D Coto Cotallo
Journal:  BMC Pediatr       Date:  2007-02-26       Impact factor: 2.125

6.  Procalcitonin is not sufficiently reliable to be the sole marker of neonatal sepsis of nosocomial origin.

Authors:  José B López Sastre; David Pérez Solís; Vicente Roqués Serradilla; Belén Fernández Colomer; Gil D Coto Cotallo; Xavier Krauel Vidal; Eduardo Narbona López; Manuel García del Río; Manuel Sánchez Luna; Antonio Belaustegui Cueto; Manuel Moro Serrano; Alfonso Urbón Artero; Emilio Alvaro Iglesias; Angel Cotero Lavín; Eduardo Martínez Vilalta; Bartolomé Jiménez Cobos
Journal:  BMC Pediatr       Date:  2006-05-18       Impact factor: 2.125

7.  Serum procalcitonin as a diagnostic marker of neonatal sepsis.

Authors:  In Ho Park; Seung Hyun Lee; Seung Taek Yu; Yeon Kyun Oh
Journal:  Korean J Pediatr       Date:  2014-10-31

8.  C-reactive protein for diagnosing late-onset infection in newborn infants.

Authors:  Jennifer Valeska Elli Brown; Nicholas Meader; Jemma Cleminson; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2019-01-14

9.  Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-1beta levels in neonatal late-onset sepsis.

Authors:  Birsen Ucar; Bilal Yildiz; M Arif Aksit; Coskun Yarar; Omer Colak; Yildiz Akbay; Ertugrul Colak
Journal:  Mediators Inflamm       Date:  2008-11-16       Impact factor: 4.711

10.  Early-Onset Neonatal Sepsis: Still Room for Improvement in Procalcitonin Diagnostic Accuracy Studies.

Authors:  Claudio Chiesa; Lucia Pacifico; John F Osborn; Enea Bonci; Nora Hofer; Bernhard Resch
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.